logo-loader
viewFaron Pharmaceuticals Ltd

Faron Pharmaceuticals Oy expands trial into ovarian cancer

Clevegen has been designed to target a range of solid tumours and people with colorectal cancer have previously received it

Faron Pharmaceuticals Ltd -

Faron Pharmaceuticals Oy (LON:FARN, First North:FARON) said its precision immunotherapy will be used in women suffering ovarian cancer.

In what’s called a second expansion cohort of the company’s phase I/II MATINS clinical trial, Faron drug Clevegen will continue to be assessed for safety and efficacy.

The treatment has been designed to target a range of solid tumours and people with colorectal cancer have previously received it.

Faron chief executive, Dr Markku Jalkanen, said data collected so far in the MATINS trial are “highly encouraging”.

He added that Clevegen establishing itself as a potential immunotherapy capable of reducing or supressing (downregulating) a range of major immune checkpoints that may inhibit the body’s own response to the disease.

“Initiation of this additional expansion cohort signals our commitment to rapidly progress the development of Clevegen in patients with limited effective treatment options," he added.

Quick facts: Faron Pharmaceuticals Ltd

Price: 470 GBX

AIM:FARN
Market: AIM
Market Cap: £203.47 m
Follow

Add related topics to MyProactive

Create your account: sign up and get ahead on news and events

NO INVESTMENT ADVICE

The Company is a publisher. You understand and agree that no content published on the Site constitutes a recommendation that any particular security, portfolio of securities, transaction, or investment strategy is...

In exchange for publishing services rendered by the Company on behalf of Faron Pharmaceuticals Ltd named herein, including the promotion by the Company of Faron Pharmaceuticals Ltd in any Content on the Site, the...

FOR OUR FULL DISCLAIMER CLICK HERE

Watch

Morning Report: FTSE 100 collapses as oil price war erupts

Headlines from the Proactive UK newsroom. Oil prices slumped by 30% on Monday as Saudi Arabia chopped prices after attempts to agree a production deal with Russia collapsed over the weekend. Brent crude plunged to US$31 a barrel after registering its largest daily drop since the Gulf...

3 weeks, 1 day ago

2 min read